Highlights

  • FY26 cochlear implant units reached 56,692, increasing 5%.
  • Sales revenue was $2,343.4 million, with 2% growth in constant currency.
  • Underlying net profit was $322.4 million, while statutory net profit reached $147.3 million.
  • The Nucleus Nexa System accounted for more than 95% of developed-market implant sales by June.
  • FY27 guidance includes underlying net profit of $330–350 million, subject to company assumptions.

Cochlear Limited (ASX:COH) develops implantable hearing solutions, including cochlear implants and bone conduction systems, alongside replacement sound processors and related services. Its FY26 reporting highlights the relationship between implant adoption, clinical referral practices and financial performance, with efforts to make adult hearing-loss assessment and referral more consistent central to the company’s 2026 strategy.

Adult Implant Access Becomes a Strategic Priority

In its August 2026 financial release, Cochlear Limited (ASX:COH) outlined plans to expand medical and professional referral pathways for adults with severe to profound hearing loss. The company said adult implant demand remains affected by inconsistent routes from diagnosis to surgery, even in markets with established reimbursement.

The company reported that medical and professional channels accounted for only 40% of adult cochlear implant referrals in the US. Its 2026 initiatives involve clinician education, digital candidate support, referral tracking and closer engagement with healthcare professionals. Clinical practice guidelines were undergoing adoption across 25 countries, while referral pilots had begun in four major US cities, with expansion planned.

FY26 Results: Implant Volumes and Margins

Cochlear Limited (ASX:COH) reported FY26 sales revenue of $2,343.4 million, an increase of 2% in constant currency but a 1% decrease on a reported basis. Cochlear implant sales reached 56,692 units, up 5%, although implant revenue was flat in constant currency at $1,435.2 million. The difference reflected a greater proportion of lower-priced emerging-market implants.

Services revenue totalled $634.9 million and acoustics revenue was $273.3 million. Gross margin was 71%, affected by product mix, manufacturing costs and foreign exchange. Underlying net profit was $322.4 million, and statutory net profit was $147.3 million, including significant cloud computing expenditure and non-cash investment-related charges. Free cash flow reached $264 million.

Nexa Technology and Hearing Care Delivery

The Nucleus Nexa System was a key FY26 product launch. By June 2026 it represented more than 95% of implant sales across developed markets, according to the company. Cochlear Limited (ASX:COH) described the platform as upgradeable through firmware and intended to support future clinical features, including additional diagnostic information and more personalised implant programming.

Further technology work includes drug-eluting electrodes and a totally implantable cochlear implant. Research and development spending increased 15% in FY26.

FY27 Guidance and Operating Considerations

For FY27, Cochlear Limited (ASX:COH) stated an expectation of low single-digit sales revenue growth in constant currency and underlying net profit of $330–350 million. It expected gross margin of approximately 70%–71%. These are management forecasts, not achieved results, and depend on factors including market conditions, manufacturing recovery and currency movements.

Risks identified in its 2026 reporting include delayed insurance approvals, uneven procedure demand, changing Chinese reimbursement pricing, disruption in the Middle East and foreign exchange exposure. Its efforts to improve adult referral pathways will also require clinical engagement and sustained implementation across different health systems.

Key Insights

Cochlear Limited (ASX:COH) recorded higher implant volumes but lower underlying profitability in FY26. Its adult referral strategy addresses how eligible patients move through clinical assessment to treatment, while the Nexa platform addresses device capabilities. Future company disclosures can show whether these operational initiatives coincide with improved implant sales, margins and access to hearing care.